Androgen Deprivation Therapy (ADT)

What is ADT?

  • Androgens are hormones that promote male characteristics such as facial hair, sexual function and muscle mass. Testosterone is the main androgen.
  • Prostate cancer cells need androgens to grow.
  • Androgen deprivation therapy (ADT) is a type of treatment for prostate cancer that blocks the effects of androgens and can slow prostate cancer growth.
  •  “Hormone therapy” is another name for ADT.
  • This therapy affects the whole body rather than a particular area.
  • For more information about androgens, see here.
What is done? ADT is usually given as pills or injections. In rare cases it can involve surgery to remove one or both of the testicles. For more information about types of ADT see here
What can I expect? ADT is used to slow the growth of prostate cancer and can also help manage some of the symptoms associated with advanced cancer.
  • Cancer that has spread outside the prostate
  • Recurrence of prostate cancer after another therapy has been used
  • Men who are at high risk of experiencing cancer recurrence after surgery or radiation therapy
What are the possible side-effects and risks? As with all treatments, ADT carries possible side-effects and risks. See here for a list of what these might be. Don’t be alarmed: talk to your doctor and health care team to find out how your treatment might affect you and what you can do to manage any side-effects

For more information and support:


Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More

Prostate Cancer Canada launches first national program in radioligand therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.
More


Click here for news archive